Guardant Health GH Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total Revenue by Product | |||||
| Biopharma and data | $210.13M+18.3% | $177.58M+30.2% | $136.35M— | —— | |
| Licensing and other | $8.56M-36.5% | $13.49M-43.1% | $23.72M— | —— | |
| Oncology | $683.6M+25.9% | $542.83M+34.4% | $403.88M— | —— | |
| Screening | $79.73M+1,456% | $5.12M— | $0— | —— | |
| Revenue by Geography | |||||
| International | $58.74M+40.3% | $41.85M+11.8% | $37.42M+29.4% | $28.92M+37.1% | |
| United States | $923.28M+32.4% | $697.16M+32.4% | $526.52M+25.2% | $420.62M+19.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Guardant Health break its business down?
- Guardant Health (GH) reports total revenue by product across 4 parts — Biopharma and data, Licensing and other, Oncology and Screening. Each is extracted from the segment footnotes and tracked over time.
- Where does Guardant Health's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Guardant Health's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
